REMEDIUMREMEDIUM1561-59362658-3534Joint-Stock Company Chicot96710.21518/1561-5936-2020-7-8-34-41Original ArticleAnalysis of the market of products based on plant-based raw materials used in urologySafonovaN. V.noemail@neicon.ruTrofimovaE. O.noemail@neicon.ruEvalarSaint Petersburg State Chemical Pharmaceutical University071220207-8344118032022Copyright © 2020,2020Introduction. The wide prevalence of diseases of the genitourinary system determines the need to use a variety of tools for their treatment and prevention, including plant-based raw materials.The purpose of the study is to determine the main characteristics and trends in the development of the market of urological medicines and dietary supplements plant-based on raw materials, as well as the competitive positions of foreign and domestic manufacturers in this segment. Research methods. The study was conducted using the DSM Group pharmacy sales database, official sources of information about the registration of medicines and dietary supplements, and clinical recommendations.Results. Pharmacy sales of herbal medicines and dietary supplements used in urology in 2018 amounted to 32 million packages worth14,4 billion rubles in retail prices. Drugs accounts for 78,5% of the market structure in terms of value and 82,8% - in kind. More than half of the total market is occupied by funds used for infectious and inflammatory diseases, where the share of drugs accounts for more than 90%. Russian companies account for 9% of the drugs segment and 64,2% of dietary supplements in value terms.Conclusion. Russian manufacturers occupy relatively weak competitive positions in relation to leading foreign companies due to the use of outdated forms of production, as well as focusing on the dietary supplements market.russian pharmaceutical marketmedicinesdietary supplementsplant raw materialsurological diseasesроссийский фармацевтический рыноклекарственные препаратыбиологически активные добавкирастительное сырьеурологические заболевания1.Заболеваемость населения по основным классам болезней (28.11.2019). Росстат. Режим доступа: https://www.gks.ru/ folder/13721.2.Уварова Ю. Рынок препаратов для лечения урологических заболеваний. Ремедиум. 2012;(2):40-43. Режим доступа: http://www.remedium-journal.ru/arhiv/detail. php?ID=50941&num=%B92&sec_id=5240.3.Urinary tract infection (recurrent): antimicrobial prescribing. NICE guideline. October 2018. Available at: https://www. nice.org.uk/guidance/ng112.4.Клинические рекомендации. Цистит бактериальный у взрослых. Российское общество урологов. М.; 2019. 32 с.5.Клинические рекомендации. Доброкачественная гиперплазия предстательной железы. Российское общество урологов. М.; 2019. 74 с.6.Дремова Н.Б., Овод А.И. Лекарственные аспекты лечения доброкачественной гиперплазии предстательной железы (рынок, стоимость, лекарственная терапия, мнения больных). Ремедиум. 2005;(4):36-41.7.Дремова Н.Б., Овод А.И. Маркетинговые исследования лекарственного обеспечения больных доброкачественной гиперплазией предстательной железы. Курский научно- практический вестник «Человек и его здоровье». 2006;3:41-54.8.Фармацевтический рынок России. Годовой отчет - 2018. DSM Group. Режим доступа: https://www.dsm.ru/docs/analytics/ Annual_report_2018_DSM.pdf.